Peptides DB
Research-centric peptide and protocol reference hub

BAM-15 record · updated 7h ago

Metabolic & appetiteNeuro & moodGrade B · human evidenceResearch use only
All 6 studiesJump to the evidenceCompare
What is BAM-15 used for?

BAM-15 is a mitochondrial protonophore uncoupler studied preclinically for obesity, insulin resistance, and metabolic dysfunction by increasing energy expenditure without raising heart rate.

How it works: mitochondrial protonophore uncoupler

Primarily researched for · Metabolic & appetite

Development stage

where BAM-15 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 6 registered trials. It describes the research record, not a recommendation.

Identity
NameBAM-15
Full name—
Sequence—
ClassMetabolic
Research levelPreclinical
Discovered byCurated master list · 2026
Pharmacology
Mechanismmitochondrial protonophore uncoupler
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
Metabolic & appetite: Healing 0.0, Muscle 0.0, Metabolic 4.0, Neuro 1.0, Sleep 0.0, Immune 0.0, Skin 0.0Metabolic & appetite — 4.0 / 5Neuro & mood — 1.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin0.00.04.01.00.00.00.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 28, 2026. How this works →
Research stats
Total studies6
Human / animal / cellular5 / 1 / 0
Highest trial phasePreclinical
Years covered2023–2026
Latest study7d ago
Publication history
20232026
Research funding
94,652 NIH projects · $34.5M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

6 rowsOpen in the library →
StudyTypeYearSummary depth
Blood-based RNA-Seq of 5412 individuals with rare disease identifies new candidate diagnoses in the National Genomic Research Library
Finding20% of the cohort had at least one outlier event in a disorder-relevant gene.
Human2026Full text read0.80
A Spatio-Temporal Modelling of Climate Variability on Respiratory Disease Morbidity in Kampala City, Uganda
FindingStrong spatial clustering observed (edf ≈ 4, p < 0.001).
Human2026Full text read0.80
<i>PTPN1</i> -related autoinflammation is a common cause of Aicardi-Goutières Syndrome with reduced penetrance
FindingMedian age of onset is 1.75 years (IQR 0.67), significantly later than other AGS genotypes (p<0.0001).
Human2026Full text read0.80
Vrc01-class Precursor Frequency in an African Population is Influenced by Ighv1-2 Allelic Composition and Not Malaria Exposure
FindingNot reported in abstract.
Human2026Full text read0.70
Prevalence and Antimicrobial Resistance of <i>Salmonella</i> spp., <i>Shigella</i> spp., and <i>Listeria monocytogenes</i> in Poultry Feeds and Ready-to-Eat Foods: A Farm-to-Fork Study in Conflict-Affected Maiduguri, Nigeria
Finding10.0% prevalence of Salmonella spp. in poultry feeds (95% CI 5.8–16.8), n=120.
Human2026Full text read0.80
Endogenous Energy Stores Maintain a High ATP Concentration for Hours in Glucose-Depleted Cultured Primary Rat Astrocytes.
Finding27.9 ± 4.7 nmol/mg specific ATP content.
Animal2023Full text read0.80